Converting biology into clinical benefit: Lessons learned from BRAF inhibitors

Jennifer McQuade; Michael A. Davies

doi:10.2217/MMT.15.18

Converting biology into clinical benefit: Lessons learned from BRAF inhibitors

Jennifer McQuade, Michael A. Davies

Melanoma Medical Oncology

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

The identification and pharmacological targeting of activating BRAF mutations in melanoma has led to significant improvements in patient outcomes. This perspective paper illustrates the lessons learned from the study of BRAF mutations and the development of BRAF inhibitors. The relevance of these lessons to the development of future targeted therapies is highlighted.

Original language	English (US)
Pages (from-to)	241-254
Number of pages	14
Journal	Melanoma Management
Volume	2
Issue number	3
DOIs	https://doi.org/10.2217/MMT.15.18
State	Published - 2015

Keywords

BRAF
Melanoma
NRAS
PI3K-AKT pathway
Resistance
Targeted therapy

ASJC Scopus subject areas

Oncology
Dermatology

Access to Document

10.2217/MMT.15.18

Cite this

@article{3de33e37d3d54dedbea5d0d7cbd5a228,

title = "Converting biology into clinical benefit: Lessons learned from BRAF inhibitors",

abstract = "The identification and pharmacological targeting of activating BRAF mutations in melanoma has led to significant improvements in patient outcomes. This perspective paper illustrates the lessons learned from the study of BRAF mutations and the development of BRAF inhibitors. The relevance of these lessons to the development of future targeted therapies is highlighted.",

keywords = "BRAF, Melanoma, NRAS, PI3K-AKT pathway, Resistance, Targeted therapy",

author = "Jennifer McQuade and Davies, {Michael A.}",

note = "Publisher Copyright: {\textcopyright} 2015 Future Medicine Ltd.",

year = "2015",

doi = "10.2217/MMT.15.18",

language = "English (US)",

volume = "2",

pages = "241--254",

journal = "Melanoma Management",

issn = "2045-0885",

publisher = "Future Medicine Ltd.",

number = "3",

}

TY - JOUR

T1 - Converting biology into clinical benefit

T2 - Lessons learned from BRAF inhibitors

AU - McQuade, Jennifer

AU - Davies, Michael A.

PY - 2015

Y1 - 2015

N2 - The identification and pharmacological targeting of activating BRAF mutations in melanoma has led to significant improvements in patient outcomes. This perspective paper illustrates the lessons learned from the study of BRAF mutations and the development of BRAF inhibitors. The relevance of these lessons to the development of future targeted therapies is highlighted.

AB - The identification and pharmacological targeting of activating BRAF mutations in melanoma has led to significant improvements in patient outcomes. This perspective paper illustrates the lessons learned from the study of BRAF mutations and the development of BRAF inhibitors. The relevance of these lessons to the development of future targeted therapies is highlighted.

KW - BRAF

KW - Melanoma

KW - NRAS

KW - PI3K-AKT pathway

KW - Resistance

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85011594795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011594795&partnerID=8YFLogxK

U2 - 10.2217/MMT.15.18

DO - 10.2217/MMT.15.18

M3 - Review article

C2 - 26594316

AN - SCOPUS:85011594795

SN - 2045-0885

VL - 2

SP - 241

EP - 254

JO - Melanoma Management

JF - Melanoma Management

IS - 3

ER -

Converting biology into clinical benefit: Lessons learned from BRAF inhibitors

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this